Applications des modèles physiologiques à l'analyse de données de toxicocinétique

 Access to full text

 Full (PDF)

1. AARONS L. (1992). Population pharmacokinetics. International Journal of Clinical Pharmacology, Therapy, and Toxicology 30, 520-522. 
2. ANDERSEN M. E. (1995). Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicology Letters 79, 35-44. 
3. ARMS A. D. and C. C. TRAVIS (1988). Reference Physiological Parameters in Pharmacokinetics modelling. 
4. BAILER A. J. and D. A. DANKOVIC (1997). An introduction to the use of physiologically based pharmacokinetic models in risk assessment. Statistical Methods in Medical Research 6, 341-358. 
5. BALANT L. P. and M. GEX-FABRY (1990). Physiological pharmacokinetic modelling. Xenobiotica 20, 1241-1257. 
6. BERNARDO J. M. and A. F. M. SMITH (1994). Bayesian Theory. New York, Wiley. Zbl0943.62009MR1274699
7. BERNIER J., E. PARENT and J. J. BOREUX (2000). Traitement bayesien des incertitudes. Paris, Lavoisier. 
8. BOIS F. Y. (2003). Modélisation toxicocinétique de la concentration de 2,3,7,8-tetrachloro-p-dioxine après ingestion chez la femme. Environnement, Risques et Santé 2(1), 45-53. 
9. BOIS F. Y., A. GELMAN, J. JIANG, et al (1996). Population toxicokinetics of tetrachloroethylene. Archives of Toxicology 70(6), 347-355. 
10. BOIS F. Y., E. JACKSON, K. PEKARI, et al (1996). Population toxicokinetics of benzene. Environmental Health Perspectives 104 (suppl. 6), 1405-1411. 
11. BOIS F. Y. and D. MASZLE (1997). MCSim : a simulation program. Journal of Statistical Software 2(9), http://toxi.ineris.fr/activites/toxicologie_quantitative/mcsim/mcsim.php. 
12. BOIS F. Y., T. J. SMITH, A. GELMAN, et al (1999). Optimal design for a study of butadiene toxicokinetics in humans. Toxicological Sciences : an Official Journal of the Society of Toxicology 49(2), 213-224. 
13. BROWN R. P., M. D. DELP, S. L. LINDSTEDT, et al (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicology and Industrial Health 13(4), 407-484. 
14. CLARET L. and A. ILIADIS (1996). Nonparametric density estimation applied to population pharmacokinetics. Math. Biosci. 133(1), 51-68. Zbl0844.92008
15. DAVIDSON I. W. F., J. C. PARKER and R. P. BELILES (1986). Biological basis for extrapolation across mammalian species. Regulatory Toxicology and Pharmacology 6, 211-237. 
16. DAVIES B. and T. MORRIS (1993). Physiological parameters in laboratory animals and humans. Pharmaceutical Research 10, 1093-1095. 
17. GELMAN A., F. Y. BOIS and J. JIANG (1996). Physiological pharmacokinetic analysis using population modeling and informative prior distributions. Journal of the American Statistical Association 91, 1400-1412. Zbl0882.62103
18. GELMAN A., J. B. CARLIN, H. S. STERN, et al (1995). Bayesian Data Analysis. London, Chapman & Hall. Zbl0914.62018MR1385925
19. GERLOWSKI L. E. and R. K. JAIN (1983). Physiologically based pharmacokinetic modelling : principles and applications. Journal of Pharmaceutical Sciences 72, 1103-1127. 
20. GILKS W. R., S. RICHARDSON and D. J. SPIEGELHALTER (1996). Markov Chain Monte Carlo in Practice. London, Chapman & Hall. Zbl0832.00018MR1397966
21. GREENLAND S. (2001). Sensitivity analysis, Monte Carlo risk analysis, and Bayesian uncertainty assessment. Risk Analysis : an Official Publication of the Society for Risk Analysis 21(4), 579-583. 
22. HAMMERSLEY J. M. and D. C. HANDSCOMB (1964). Monte Carlo Methods. London, Chapman and Hall. Zbl0121.35503MR223065
23. HOPKINS J. C. and R. J. LEIPOLD (1996). On the dangers of adjusting the parameter values of mechanism-based mathematical models. Journal of Theoretical Biology 183, 417-427. 
24. INGS R. M. (1990). Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20, 1201-1231. 
25. International Commission on Radiological Protection (ICRP) (2003). Basic Anatomical and Physiological Data for Use in Radiological Protection : Reference Values. Stockholm, J. Valentin. 
26. KOHN M. C. and R. L. MELNICK (1993). Species differences in the production and clearance of 1,3-butadiene metabolites : a mechanistic model indicates predominantly physiological, not biochemical, control. Carcinogenesis 14(4), 619-628. 
27. KOHN M. C. and R. L. MELNICK (1996). Effects of the structure of a toxicokinetic model of butadiene inhalation exposure on computed production of carcinogenic intermediates. Toxicology 113(1-3), 31-39. 
28. LAWRENCE G. S. and F. A. GOBAS (1997). A pharmacokinetic analysis of interspecies extrapolation in dioxin risk assessment. Chemosphere 35(3), 427-452. 
29. LOUIS T. A. (1991). Assessing, accommodating, and interpreting the influences of heterogeneity. Environmental Health Perspectives 90, 215-222. 
30. LUECKE R. H., W. D. WOSILAIT, B. A. PEARCE, et al (1997). A computer model and program for xenobiotic disposition during pregnancy. Computer Methods and Programs in Biomedicine 53(3), 201-224. 
31. MEZZETTI M., J. G. IBRAHIM, F. Y. BOIS, et al (2003). A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism. Journal of the Royal Statistical Society, Series C-Applied Statistics 52, 291-305. Zbl1111.62356MR1997291
32. OFLAHERTY E. J. (1997). Pharmacokinetics, pharmacodynamics, and prediction of developmental abnormalities. Reproductive Toxicology 11(2-3) : 413-416. 
33. RACINE-POON A. and A. F. SMITH (1990). Population models. Statistical Methodology in the Pharmaceutical Sciences. D. A. Berry, New York, Marcel Dekker, Inc., 139-162. 
34. RACINE-POON, A. and J. WAKEFIELD (1998). Statistical methods for population pharmacokinetic modelling. Statist. Methods Med. Res. 7(1), 63-84. 
35. ROBERT C. (1996). Méthodes de Monte Carlo par Chaînes de Markov. Paris, Economica. Zbl0917.60007MR1419096
36. ROWLAND M. and T. N. TOZER (1989). Clinical Pharmacokinetics : Concepts and Applications. Philadelphia, Lea &, Febiger. 
37. SHEINER L. B. (1984). The population approach to pharmacokinetic data analysis : rationale and standard data analysis methods. Drug Metabolism Reviews 15, 153-171. 
38. SHEINER L. B. and S. L. BEAL (1982). Bayesian individualization of pharmacokinetics : simple implementation and comparison with non-Bayesian methods. Journal of Pharmaceutical Sciences 7 1 , 1344-1348. 
39. SWEENEY L. M., T. R. TYLER, C. R. KIRMAN, et al. (2001). Proposed occupational exposure limits for select ethylene glycol ethers using PBPK models and Monte Carlo simulations. Toxicological Sciences 62(1), 124-139. 
40. VAN der MOLLEN G. W., S. A. L. M. KOOIJMAN and W. SLOB (1996). A generic toxicokinetic model for persistent lipophilic compounds in humans : an application to TCDD. Fundamental and Applied Toxicology 31, 83-94. 
41. WAKEFIELD J. and J. BENNETT (1996). The Bayesian modeling of covariates for population pharmacokinetic models. Journal of the American Statistical Association 91, 917-927. Zbl0882.62104
42. WAKEFIELD J. and S. WALKER (1997). Bayesian nonparametric population models : formulation and comparison with likelihood approaches. Journal of Pharmacokinetics and Biopharmaceutics 25(2), 235-53. 
43. WANG X., M. J. SANTOSTEFANO, M. J. DEVITO, et al. (2000). Extrapolation of a PBPK model for dioxins across dosage regimen, gender, strain, and species. Toxicological Sciences 56, 49-60. 
44. WATANABE K. H. and F. Y. BOIS (1996). Interspecies extrapolation of physiological pharmacokinetic parameter distributions. Risk Analysis : an Official Publication of the Society for Risk Analysis 16(6) : 741-754. 

1. Philippe Hubert, Caractérisation de l'incertitude associée aux inférences dans l'évaluation de la mortalité attribuée à des facteurs de risque